S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL

• Aleksandra Urban,
• Johanne Hermansen,
• Yanping Yin,
• Weikaixin Kong,
• Rebecca Teglgaard,
• Christian Brieghel,
• Sabina Kersting,
• Geir E. Tjønnfjord,
• Mark-David Levin,
• Hoa T. T. Tran,
• Mattias Mattsson,
• Juha Ranti,
• Gerrit-Jan Veldhuis,
• Caspar Da Cunha-Bang,
• Rogier Mous,
• Julie Dubois,
• Arnon Kater,
• Carsten Niemann,
• Tero Aittokallio,
• Sigrid Skånland

Affiliations

Aleksandra Urban

1 Oslo University Hospital, Department of Cancer Immunology, Oslo, Norway

Johanne Hermansen

1 Oslo University Hospital, Department of Cancer Immunology, Oslo, Norway

Yanping Yin

1 Oslo University Hospital, Department of Cancer Immunology, Oslo, Norway

Weikaixin Kong

4 University of Helsinki, Institute for Molecular Medicine Finland (FIMM), HiLIFE, Helsinki, Finland

Rebecca Teglgaard

5 Rigshospitalet, Department of Hematology, Copenhagen, Denmark

Christian Brieghel

5 Rigshospitalet, Department of Hematology, Copenhagen, Denmark

Sabina Kersting

6 Haga Ziekenhuis, Department of Hematology, Den Haag, The Netherlands

Geir E. Tjønnfjord

2 University of Oslo, K.G. Jebsen Centre for B Cell Malignancies, Oslo, Norway

Mark-David Levin

7 Albert Schweitzer Hospital, Department of Internal Medicine, Dordrecht, The Netherlands

Hoa T. T. Tran

8 Akershus University Hospital, Department of Hematology, Lørenskog, Norway

Mattias Mattsson

9 Uppsala University Hospital, Department of Hematology, Uppsala, Sweden

Juha Ranti

10 Turku University Hospital, Department of Hematology and Stem Cell Transplantation Unit, Division of Medicine, Turku, Finland

Gerrit-Jan Veldhuis

11 Antonius Ziekenhuis, Department of Hematology, Sneek, The Netherlands

Caspar Da Cunha-Bang

5 Rigshospitalet, Department of Hematology, Copenhagen, Denmark

Rogier Mous

12 UMC Utrecht Cancer Center, Department of Hematology, Utrecht, The Netherlands

Julie Dubois

13 Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University medical Centers, University of Amsterdam, Department of Hematology, Amsterdam, The Netherlands

Arnon Kater

13 Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University medical Centers, University of Amsterdam, Department of Hematology, Amsterdam, The Netherlands

Carsten Niemann

5 Rigshospitalet, Department of Hematology, Copenhagen, Denmark

Tero Aittokallio

4 University of Helsinki, Institute for Molecular Medicine Finland (FIMM), HiLIFE, Helsinki, Finland

Sigrid Skånland

1 Oslo University Hospital, Department of Cancer Immunology, Oslo, Norway